Previous Close | 107.27 |
Open | 106.52 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 105.89 - 106.87 |
52 Week Range | 89.67 - 121.64 |
Volume | |
Avg. Volume | 5,727,750 |
Market Cap | 183.877B |
Beta (5Y Monthly) | 0.74 |
PE Ratio (TTM) | 33.01 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.20 (2.08%) |
Ex-Dividend Date | Apr 12, 2024 |
1y Target Est | N/A |
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.